Log in

NASDAQ:MRTXMirati Therapeutics Stock Price, Forecast & News

$101.62
+0.62 (+0.61 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$97.79
Now: $101.62
$101.64
50-Day Range
$73.43
MA: $90.85
$108.44
52-Week Range
$66.01
Now: $101.62
$132.59
Volume315,732 shs
Average Volume554,951 shs
Market Capitalization$4.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More
Mirati Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.34 million
Book Value$9.67 per share

Profitability

Net Income$-213,260,000.00
Net Margins-10,983.84%

Miscellaneous

Employees63
Market Cap$4.43 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

How has Mirati Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRTX stock has increased by 31.3% and is now trading at $101.62. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mirati Therapeutics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mirati Therapeutics.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mirati Therapeutics.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($2.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.66) by $0.36. The biotechnology company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. Mirati Therapeutics had a negative return on equity of 53.25% and a negative net margin of 10,983.84%. The business's revenue was down 78.5% on a year-over-year basis. View Mirati Therapeutics' earnings history.

What price target have analysts set for MRTX?

17 Wall Street analysts have issued 12 month target prices for Mirati Therapeutics' shares. Their forecasts range from $83.00 to $151.00. On average, they anticipate Mirati Therapeutics' stock price to reach $113.56 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price. View analysts' price targets for Mirati Therapeutics.

Has Mirati Therapeutics been receiving favorable news coverage?

News articles about MRTX stock have been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mirati Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutMirati Therapeutics.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), DexCom (DXCM), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Paypal (PYPL), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
  • Temre Johnson, Director of Investor Relations & Corp. Communications

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.84%), Janus Henderson Group PLC (5.38%), Sands Capital Management LLC (5.15%), Wellington Management Group LLP (3.98%), Orbimed Advisors LLC (3.26%) and State Street Corp (2.91%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Isan Chen, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View institutional ownership trends for Mirati Therapeutics.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Two Sigma Advisers LP, Pictet Asset Management Ltd., Lord Abbett & CO. LLC, Ghost Tree Capital LLC, Rafferty Asset Management LLC, and Eaton Vance Management. Company insiders that have sold Mirati Therapeutics company stock in the last year include Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Isan Chen, and Michael G Grey. View insider buying and selling activity for Mirati Therapeutics.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Sands Capital Management LLC, Janus Henderson Group PLC, BlackRock Inc., Orbimed Advisors LLC, Geode Capital Management LLC, Nuveen Asset Management LLC, and Castleark Management LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, and Venbio Select Advisor Llc. View insider buying and selling activity for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $101.62.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $4.43 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.